More Americans now die from hepatitis C infection than from HIV, researchers from the Centers for Disease Control and Prevention reported.
One possible step forward would be a change in screening policy for hepatitis C, according to David Rein, PhD, of the social science research organization NORC at the University of Chicago in Atlanta, and colleagues.
Currently, the CDC recommends antibody screening for people with such risk factors or indicators as a history of injection-drug use or elevated alanine aminotransferase levels.Depending on the form of subsequent treatment, the screening would prevent between 82,300 and 121,000 deaths, with an incremental cost-effectiveness ratio per quality-adjusted life year gained ranged from $15,700 to $35,700, Rein and colleagues calculated.
Read the full story at: http://hcp.lv/xyA6p0
Source: MedPage Today
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More